Page last updated: 2024-11-11

anatibant

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LF 16-0687: a potent non-peptide bradykinin B2 receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9831652
CHEMBL ID2107725
CHEBI ID138828
SCHEMBL ID6945415
MeSH IDM0540856

Synonyms (26)

Synonym
(2s)-n-[3-[(4-carbamimidoylbenzoyl)amino]propyl]-1-[2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxymethyl]phenyl]sulfonylpyrrolidine-2-carboxamide
lf160687
gtpl679
anatibant
lf16-0687
1-((2,4-dichloro-3-(((2,4-dimethylquinolin-8-yl)oxy) methyl)phenyl)sulfonyl)-n-(3-((4-(aminoimethyl) phenyl) carbonylamino)propyl)-2(s)-pyrrolidinecarboxamide
lf 16-0687
CHEBI:138828
2-mercapto-pyridin-3-ol
209733-45-9
(2s)-n-(3-(4-carbamimidoylbenzamido)propyl)-1-(2,4-dichloro-3-((2,4-dimethyl-8-quinolyloxy)methyl)phenylsulfonyl)pyrrolidine-2-carboxamide
anatibant [inn]
clo4jrd21f ,
unii-clo4jrd21f
(2s)-n-(3-(4-carbamimidoylbenzamido)propyl)-1-{2,4-dichloro-3-((2,4-dimethyl-8-quinolyloxy)methyl)phenylsulfonyl}pyrrolidine-2-carboxamide
C20010
xy-2405
xy2405
CHEMBL2107725
DB05038
SCHEMBL6945415
DTXSID40175160
Q27074461
209733-45-9 (free base)
(s)-n-(3-(4-carbamimidoylbenzamido)propyl)-1-((2,4-dichloro-3-(((2,4-dimethylquinolin-8-yl)oxy)methyl)phenyl)sulfonyl)pyrrolidine-2-carboxamide
AKOS040747817

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" To address this issue, a dose-response trial that would investigate the effects of Anatibant on the incidence of raised ICP and on functional outcome in severe TBI patients is needed."( A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury.
Combal, JP; Guy, M; Layani, L; Marmarou, A; Marquer, C; Murphey, L; Roy, F, 2005
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
proline derivativeAn amino acid derivative resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of proline by a heteroatom. The definition normally excludes peptides containing proline residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346473Human B2 receptor (Bradykinin receptors)1999Immunopharmacology, Sep, Volume: 43, Issue:2-3
Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist.
AID1347008Rat B2 receptor (Bradykinin receptors)1999Immunopharmacology, Sep, Volume: 43, Issue:2-3
Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (6.25)18.2507
2000's28 (87.50)29.6817
2010's2 (6.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.95 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.25%)5.53%
Reviews2 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]